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Introduction
The lymphatic vascular system is involved in many pathological 
processes, including lymphedema and the metastatic spread of 
cancer. Despite the importance of the lymphatic system for 
human health, our knowledge of lymphatic vessel development 
lags considerably behind that of blood vascular development, 
and it is only in recent years that some of the molecules that 
regulate lymphangiogenesis have been identified (for review 
see Tammela et al., 2005). The data presented in this study 
establish the transcription factor TBX1 as a new player in 
lymphangiogenesis.
TBX1 encodes a T box transcription factor involved in the 
22q11 deletion syndrome (22q11DS), also known as DiGeorge 
syndrome. 22q11DS patients have a complex phenotype that 
includes cardiovascular defects, craniofacial dysmorphism, hypo-
calcemia, immune deficiency, behavioral disorders, and psychi-
atric diseases. Most of the physical abnormalities are caused by 
TBX1 haploinsufficiency (Yagi et al., 2003), and we have shown 
that TBX1 may contribute to the psychiatric disorders (Paylor 
et al., 2006). Lymphatic defects have not been reported in 
22q11DS patients, with a single exception (Mansir et al., 1999). 
However, the recurrent infections associated with the disease 
may be contributed by subtle lymphatic abnormalities in addi-
tion to the known T cell immune deficiency.
In the mouse, mutation of Tbx1 recapitulates the common 
physical abnormalities seen in patients (Jerome and Papaioannou, 
2001; Lindsay et al., 2001; Merscher et al., 2001). During 
mouse development, Tbx1 is widely expressed in the develop-
ing pharynx, ear, and the endothelial lining of some blood ves-
sels (Vitelli et al., 2002; Paylor et al., 2006). Intriguingly, a 
Lymphatic dysfunction causes several human diseases, and tumor lymphangiogenesis is implicated in cancer spreading. TBX1 is the major gene for DiGeorge syn-
drome, which is associated with multiple congenital anom-
alies. Mutation of Tbx1 in mice recapitulates the human 
disease phenotype. In this study, we use molecular, cellular, 
and genetic approaches to show, unexpectedly, that Tbx1 
plays a critical role in lymphatic vessel development and 
regulates the expression of Vegfr3, a gene that is essential 
for lymphangiogenesis. Tbx1 activates Vegfr3 transcription 
in endothelial cells (ECs) by binding to an enhancer ele-
ment in the Vegfr3 gene. Conditional deletion of Tbx1  
in ECs causes widespread lymphangiogenesis defects in 
mouse embryos and perinatal death. Using the mesentery 
as a model tissue, we show that Tbx1 is not required for 
lymphatic EC differentiation; rather, it is required for the 
growth and maintenance of lymphatic vessels. Our findings 
reveal a novel pathway for the development of the lym-
phatic vessel network.
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A similar pathology has been reported in several mouse 
mutants that have mutations in genes involved in lymphatic ves-
sel development (for review see Tammela et al., 2005), suggest-
ing that Tbx1 may be required in ECs for lymphangiogenesis. 
In view of the dramatic phenotype seen in Tie2-Cre; Tbx1flox/lacz 
mutants, we first evaluated lymphangiogenesis in the gastro-
intestinal (GI) tract of preterm embryos. For this, we performed 
immunostaining on isolated GI tracts of E18.5 embryos using 
antibodies against three EC-specific genes, CD31 (Pecam-1), 
Vegfr3, and Lyve1. Anti–Pecam-1 identifies ECs of arteries, 
veins, and lymphatic vessels, whereas anti-Vegfr3 and anti-
Lyve1 are specific for lymphatic ECs (LECs) at this embryonic 
stage. Anti–Pecam-1 revealed an overall reduction in the num-
ber of vessels in the mesentery of both Tie2-Cre; Tbx1flox/lacz  
mutants (Fig. 1, B and B) and Tbx1lacz/lacz (null) mutants (not 
depicted). We used anti-Vegfr3 to confirm that the missing ves-
sels were indeed lymphatic vessels (Fig. 1, C and C). Similar 
results were obtained with anti-Lyve1 (Fig. S1), thereby con-
firming that the lack of staining with anti-Vegfr3 was caused by 
the absence of the lymphatic vessels. Thus, EC-specific loss of 
Tbx1 causes a developmental failure of the entire GI lym-
phatic vasculature.
variety of vascular abnormalities has been reported in 22q11DS 
patients (D’Antonio and Marsh, 1987; MacKenzie-Stepner 
et al., 1987; Mansour et al., 1987). In this study, we sought 
to establish the requirement for Tbx1 in endothelial cells 
(ECs) and found an unexpected and critical role in lymphatic 
vessel development.
Results and discussion
Loss of Tbx1 in ECs causes perinatal 
lethality and lymphatic abnormalities
We deleted Tbx1 specifically in ECs using an EC-specific Cre 
driver, Tie2-Cre (Kisanuki et al., 2001). We crossed Tie2-Cre; 
Tbx1lacz/+ mice with Tbx1flox/flox mice and genotyped 114 off-
spring at weaning. We did not recover any Tie2-Cre; Tbx1flox/lacz 
pups (i.e., null for Tbx1 in ECs and heterozygous in all other 
tissues). In contrast, this genotype was recovered at the normal 
Mendelian ratio (10/39) on embryonic day (E) 18.5. We estab-
lished that Tie2-Cre; Tbx1flox/lacz mutants died between postnatal 
day (P) 2 and 4, when they showed growth failure, dehydration, 
and abdominal chylous ascites (Fig. 1 A), which are features 
that were not present in controls (Fig. 1 A).
Figure 1. Lymphatic abnormalities in EC-
specific Tbx1-null mutants. (A) In control em-
bryos, chyle is visible in mesenteric lymphatic 
vessels (arrowheads). (A’) On P4, Tie2-Cre; 
Tbx1flox/lacz mutants show growth retardation, 
abdominal distention, and accumulation of chyle 
in the intestinal wall (arrows) and membranous 
mesentery (arrowheads). (B and B) Immuno-
histochemistry on isolated intestines at E18.5. 
Anti–Pecam-1 shows that Tie2Cre; Tbx1flox/lacz 
mutants (B) have fewer mesenteric vessels 
than controls (B). (C) Anti-Vegfr3 reveals that 
Tie2Cre/+; Tbx1flox/lacz mutants lack the mes-
enteric lymphatic vessels. (C) Control mesen-
tery is shown. L, lymphatic vessel; A, artery; 
V, vein; I, intestine. Bars, 1 mm.
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used a lacZ reporter allele (Lindsay et al., 2001) and an anti-
Tbx1 antibody. At E13.5, we identified -galactosidase (-gal) 
activity in the proximal mesentery, where it colocalized with 
anti-Vegfr3 immunostaining (Fig. 2, A and B), indicating that 
Tbx1 is expressed in the LECs of early mesenteric lymphatic 
vessels. Note that Tbx1 expression was not LEC specific at this 
or later embryonic stages, as -gal activity was also identifi-
able in some ECs of the mesenteric artery and vein. Robust 
-gal activity in lymphatic vessels continued through E16.5 
(Fig. 2, C, D, and F). Anti-Tbx1 immunostaining showed a 
similar pattern of expression (Fig. 2 E). We determined the 
time requirement for Tbx1 in mesenteric lymphangiogenesis 
using transgenic mice that carry a tamoxifen (TM)-inducible 
Cre recombinase under the control of a ubiquitous promoter 
(TgCAGG-CreERTM; Hayashi and McMahon, 2002). TgCAGG-
CreERTM; Tbx1lacz/+ male mice were bred with Tbx1flox/flox 
females. Pregnant females were injected with TM between 
E11.5 and E14.5 to effect Cre-induced excision of the floxed 
Tbx1 exon 5, and thereby gene inactivation between E12.5 and 
E15.5 (see Materials and methods). Mice with the genotype 
TgCAGG-CreERTM; Tbx1flox/lacz constituted the test group, 
whereas embryos with the genotype TgCAGG-CreERTM; Tbx1flox/+ 
constituted the control group. Embryos were collected at E18.5, 
and intestines were immunostained with anti-Vegfr3. In control 
embryos exposed to TM at E11.5, the mesenteric lymphatics 
We next examined lymphatic vessels in other tissues, in-
cluding heart, diaphragm, and skin in Tbx1lacz/+ and Tbx1lacz/lacz 
embryos at E18.5 (Fig. S2). In the heart, anti-Vegfr3 immuno-
staining revealed a severe reduction in the number of lymphatic 
vessels in Tbx1lacz/lacz embryos, with only a few vessels adjacent 
to the aorta being identifiable (Fig. S2, A–B). Anti–Pecam-1 
immunostaining showed similar staining patterns in both geno-
types (Fig. S2, C and C), although in Tbx1lacz/lacz embryos, some 
vessels were dilated, and there was a reduced vessel density. 
In the diaphragm, an extensive network of lymphatic vessels 
was observed in control embryos (Fig. S2, D and E), whereas 
in Tbx1lacz/lacz embryos, this network was severely reduced 
(Fig. S2, D and E). Similar results were obtained with anti-
Lyve1 (Fig. S2, F and F). In the skin, Tbx1lacz/lacz embryos had 
fewer subcutaneous lymphatic vessels than control embryos 
(Fig. S2, G and H and G and H, respectively). Consistent with 
this observation, Tbx1lacz/lacz embryos showed subcutaneous 
edema at E14.5 (Fig. S2, I and I).
Tbx1 is required early in mesenteric 
lymphangiogenesis
Because of the severity of the mesenteric phenotype, we focused 
our attention on the function of Tbx1 in this tissue. In the mouse, 
the first mesenteric lymphatic vessels form around E13 (van der 
Putte, 1975; Kim et al., 2007). To monitor Tbx1 expression, we 
Figure 2. Tbx1 colocalizes with LEC-specific 
markers in mesenteric lymphatic vessels.  
(A and B) LacZ reporter activity revealed 
by X-gal staining (blue) colocalizes with anti-
Vegfr3 immunostaining (brown) in mesenteric 
lymphatic vessels (arrows) of Tbx1lacZ/+ em-
bryos at E13.5. The boxed area in A is magni-
fied in B. (C and D) Colocalization of LacZ 
reporter activity and anti-Lyve1 immunostain-
ing in Tbx1lacZ/+ embryos at E14.5 (C) and 
E16.5 (D). (C, inset) X-gal staining on an 
adjacent section is shown. (E and F) Tbx1 
protein is expressed in mesenteric LECs at 
E16.5 (E, arrowheads) and has a similar 
distribution to the LacZ reporter activity at this 
stage (F). A, mesenteric artery; V, mesenteric 
vein; L, lymphatic vessel. Bars, 100 µm.
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were seen (Fig. S3 C, arrows). Induction at E14.5 resulted in 
apparently normal lymphatic vessel development at E18.5 
(Fig. S3 D). Thus, Tbx1 is required for lymphangiogenesis 
until E14. In the mouse, this is 24 h after the onset of mesen-
teric lymphangiogenesis (van der Putte, 1975). As shown in 
Fig. 2 (A and B), Tbx1 is expressed in mesenteric LECs at this 
critical stage.
Tbx1 is required for lymphatic vessel 
maintenance
We asked whether Tbx1-deficient lymphatic vessels form, and if 
so, what their fate is. To address this, we used two previously 
characterized Tbx1-null alleles, Tbx1E5 (Xu et al., 2004) and 
Tbx1Cre (Huynh et al., 2007), in conjunction with the Cre reporter 
R26R (Soriano, 1999). X-gal staining of isolated intestines at 
E14.5 shows extensive contribution of Tbx1-traced cells to the 
mesenteric vessels of control (Tbx1Cre/+; R26R) embryos (Fig. 3 A) 
and null mutant (Tbx1Cre/E5; R26R) embryos (Fig. 3 A). Double 
staining (X-gal and anti-Lyve1) of Tbx1Cre/+; R26R embryos at 
E14.5 (Fig. 3 B) and E15.5 (Fig. 3 C) revealed that the mesen-
teric lymphatic endothelium is largely composed of Tbx1-traced 
cells (Fig. 3, black arrowheads). In Tbx1Cre/E5; R26R embryos 
(Fig. 3, B and C), Tbx1-traced cells contributed to clusters of 
vessels (Fig. 3, B and C, red arrowheads) that were unlike the 
characteristic network of lymphatic vessels seen in controls. 
Nevertheless, some of these abnormal vessels were Lyve1+, indi-
cating their lymphatic nature. In the distal mesentery, -gal+  
vessels were Lyve1 negative (Fig. 3, D and D) and are likely 
tributaries of the mesenteric artery and vein (note that the punc-
tate brown signals in mutant and control sections are Lyve1+ macro-
phages). Thus, Tbx1 is not essential for mesenteric lymphatic 
vessel formation. We determined the fate of the abnormal lym-
phatic vessels at later embryonic stages. At E16.5, only a few 
-gal+ vessels were identifiable in the proximal mesentery of 
Tbx1Cre/E5; R26R embryos (Fig. 3 E), some of which were also 
Lyve1+ (Fig. 3 E, red arrowhead), whereas in the distal mesen-
tery, -gal+ vessels were Lyve1 negative, as seen at E15.5 (not 
depicted). At E18.5, -gal+ vessels were Lyve1 negative and had 
the anatomy of veins and arteries (unpublished data). Similar 
results were obtained at the aforementioned embryonic stages 
with anti-Vegfr3 (unpublished data). Thus, on a Tbx1-null back-
ground, the mesenteric lymphatic vessels form, but they are 
abnormal, they fail to extend into the distal mesentery, and be-
tween E15.5 and E16.5, they are almost completely lost. To de-
termine whether this loss is caused by cell death, we performed 
anti–caspase 3 immunostaining on isolated GI tracts of Tbx1lacZ/+ 
and Tbx1lacZ/lacZ embryos at E14.5 and E16.5. Results showed a 
significant increase in the number of apoptotic cells adjacent to 
the mesenteric artery of Tbx1lacZ/lacZ embryos (P < 0.01) at E16.5 
(Fig. S3, F–G) but not at E14.5 (Fig. S3, E, E, and G).
Tbx1 regulates transcription of growth 
factors and angiogenic markers in ECs
We next used quantitative real-time PCR (qRT-PCR) to explore 
the transcriptional response of 82 genes involved in angiogenesis 
and lymphangiogenesis (RT2Profiler PCR Array; QIAGEN) 
to TBX1 expression in cultured human umbilical vein ECs 
developed normally (Fig. S3 A). In contrast, TgCAGG-CreERTM; 
Tbx1flox/lacz mutants exposed to TM at E11.5 (Fig. S3 B) and 
E12.5 (not depicted) had no identifiable mesenteric lymphatics 
at E18.5, which is similar to Tie2-Cre; Tbx1flox/lacz and Tbx1lacz/lacz 
mutants. Induction at E13.5 resulted in near-complete absence 
of lymphatic vessels, although in two out of seven TgCAGG-
CreERTM; Tbx1flox/lacz mutants analyzed, a few Vegfr3+ vessels 
Figure 3. Fate mapping of Tbx1-expressing cells in the mesentery. (A and A) 
X-gal staining of isolated intestines at E14.5 shows extensive contribu-
tion of Tbx1-traced cells to the mesenteric vessels of control (A; Tbx1Cre/+; 
R26R) and mutant (Tbx1Cre/E5; R26R) embryos (A’). Black lines indicate 
the angle of sections in B and B. (B and B) In the proximal mesentery 
of E14.5 embryos, X-gal staining and anti-Lyve1 colocalize in mesenteric 
LECs in control (B) and mutant (B) embryos. Note the abnormal anatomy 
of the mutant lymphatic vessels (B’, red arrowheads). (C and C’) At E15.5, 
in the proximal mesentery, highly abnormal lymphatic vessels in mutant 
embryos (C’, red arrowheads) are both X-gal+ and Lyve1+. (D and D’) In 
the distal mesentery, lymphatic vessels were present in control embryos 
(D, arrowhead) but not mutant embryos (D’). Insets show the boxed area 
at higher magnification. (E and E’) At E16.5, very few X-gal+/Lyve1+ ves-
sels are identifiable (E’, red arrowhead). Note that the vasa vasorum 
(E, black arrows) is X-gal+/Lyve1 negative. A, mesenteric artery; V, mes-
enteric vein; L, lymphatic vessel; P, proximal; D, distal. Black arrowheads 
indicate lymphatic vessels. Bars, 100 µm.
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lymph sacs and in subcutaneous lymphatic vessels (unpublished 
data), both of which are present in Tbx1/ mutants, although 
they are abnormal and reduced in number.
Therefore, we focused our attention on VEGFR3, which is 
essential for lymphangiogenesis (Karkkainen et al., 2000, 2001) 
and is regulated by TBX1 in a dose-dependent manner (Fig. 4 A). 
Because HUVECs express endogenous TBX1, we knocked it down 
using siRNA to test whether VEGFR3 expression responds to 
it. We obtained an 80% reduction in TBX1 expression and a 
40% reduction in VEGFR3 expression in multiple experiments 
(Fig. 4 I). Similar experiments performed on cultured human 
microvascular LECs (HMLECs) yielded a 60% reduction in 
VEGFR3 expression (Fig. 4 J). siRNA knockdown of TBX1 
mRNA resulted in reduced TBX1 protein expression in both 
HMLECs (Fig. 4 K) and in HUVECs (not depicted).
To identify putative TBX1-responsive enhancers within 
the VEGFR3 gene, we searched for evolutionarily conserved 
DNA segments containing conserved T box–binding elements 
(TBE). A 1.1-kb segment was identified that encompassed 
intron 11-12 and contained a single TBE. We cloned this DNA 
fragment from the mouse genome and named it In11-12TBE. We 
asked whether the In11-12TBE enhancer responds to Tbx1 in a 
tissue culture system. To test this, we cotransfected JEG3 cells 
with a Tbx1 expression vector and a luciferase reporter con-
taining In11-12TBE and a basal promoter (Fig. 5 A). Overexpres-
sion of Tbx1 led to a fourfold increase in luciferase activity in 
multiple experiments (Fig. 5 B). In contrast, mutation of TBE 
(HUVECs). Among the markers of lymphangiogenesis, PROX1 
and LYVE1 did not change significantly in response to TBX1 
transfection. However, VEGFR3, PDPN, and VEGFD increased 
significantly, as did IGF1 (Fig. 4 A). We validated data obtained 
by qRT-PCR and immunocytofluorescence with VEGFD and 
IGF1 antibodies on TBX1-transfected HUVECs (Fig. 4, B–E). 
Results showed that 7% of the control cell population ex-
pressed VEGFD or IGF1 protein, and this percent increased 
two- to threefold after TBX1 transfection (Fig. 4 F). This sug-
gests that at least part of the increased level of mRNA encoding 
those proteins is caused by an increase in the number of cells 
expressing those markers. We evaluated cell proliferation by 
immunocytofluorescence with anti–phosphohistone H3. In 
HUVECs transfected with 3 µg human TBX1 expression vector, 
cell proliferation increased >1.8-fold above that of control cul-
tures (Fig. 4 G). We used Western blotting to confirm that trans-
fection of HUVECs with the TBX1-expressing vector resulted 
in increased expression of TBX1 protein (Fig. 4 H).
Tbx1 regulates VEGFR3 in ECs
Of the three most highly up-regulated genes, IGF1, VEGFD, 
and PDPN, only Pdpn loss of function in mice is associated 
with lymphatic defects, namely lymphatic vessel dilatation and 
impaired lymphatic transport (Schacht et al., 2003), which is 
unlike the lymphatic phenotype of Tbx1-null mutants. In addi-
tion, anti-VEGFD immunostaining in Tbx1-null mutants was 
normal. Specifically, it was expressed in LECs lining the jugular 
Figure 4. Tbx1 activates prolymphangio-
genic genes in ECs. (A) Fold change histogram 
representation of qRT-PCR results of RNA from 
HUVECs transfected with increasing amounts 
of TBX1 expression vector. (B–E) Anti-IGF1 
(green) and anti-VEGFD (red) staining of TBX1-
transfected HUVECs (D and E) and control cul-
tures (B and C). Arrows indicate IGF1+ and 
VEGFD+ cells. Mock transfections (B, C, and F 
[white columns]) were performed by transfect-
ing HUVECs with empty vector. TOPRO3 iden-
tifies cell nuclei. (F) More IGF1+ and VEGFD+ 
cells were present in TBX1-transfected cultures 
compared with control cultures. 500 cells 
were counted in three independent experi-
ments for each antibody. (G) Cell proliferation 
in TBX1-transfected HUVECs increased >1.8-
fold above that of control cultures. (H) West-
ern blotting reveals increased TBX1 protein 
expression after TBX1 transfection of HUVECs. 
(I and J) TBX1 and VEGFR3 mRNA levels in 
TBX1-siRNA– treated or control siRNA–treated 
HUVECs (I) and HMLECs (J) were quantified by 
qRT-PCR and normalized to GAPDH. Control 
expression levels were set to 1. In both cell 
types, TBX1 and VEGFR3 mRNA levels were 
greatly reduced after TBX1 knockdown. Values 
are mean ± SEM. (K) Western blotting with 
antibodies to TBX1 and -actin showed that 
TBX1 protein expression was reduced in HMLECs 
treated with TBX1-siRNA. Bars, 100 µm.
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generated transgenic embryos carrying In11-12TBE with the TBE 
mutated. We obtained 11 transgenic embryos with the mutant 
transgene (In11-12TBEmut-lacZ) at E15.5, of which five were 
-gal+. In these embryos, no -gal–expressing cells were seen 
in Vegfr3+ mesenteric LECs (Fig. 5, D–E) or in skin or heart 
lymphatic vessels (not depicted), indicating that the mutated 
transgene was not activated in these cells. These results demon-
strate that In11-12TBE functions as an LEC enhancer in vivo and 
that its activity depends on its TBE. In transgenic embryos car-
rying the wild-type or mutated TBE, we observed strong X-gal 
staining in ECs of the mesenteric artery (Fig. 5, D–E). Vegfr3 
is not normally expressed in arterial ECs at this stage, suggest-
ing that the endogenous Vegfr3 gene harbors a suppressor ele-
ment that is absent in the transgene.
In summary, our data show that Tbx1 is required in ECs 
for development of the GI lymphatic vasculature. In mice, the 
loss of this population of lymphatic vessels is lethal after birth. 
Elsewhere, lymphatic vessels develop in both Tie2-Cre; Tbx1flox/lacz 
mutants and in Tbx1 germline-null mutants, although in the tis-
sues surveyed, they were much reduced in number and abnormal. 
(see Materials and methods) made this enhancer unresponsive 
to Tbx1 (Fig. 5 B), demonstrating that its activation is medi-
ated by this TBE.
We next determined whether this TBE is occupied by 
endogenous TBX1 using chromatin immunoprecipitation (ChIP) 
from HUVECs, which express endogenous TBX1 and VEGFR3. 
DNA fragments precipitated by anti-TBX1 were purified and 
tested for the presence of the aforementioned TBE by PCR. 
Results showed enrichment of DNA fragments containing the 
TBE in the ChIP sample (Fig. 5 C), indicating that TBX1 occu-
pies this site in these cells.
Next, to test whether In11-12TBE functions as an LEC en-
hancer in vivo, we generated transient transgenic mice carrying 
an HSP-lacZ reporter driven by In11-12TBE with either the wild-
type or mutated TBE (see Materials and methods). We obtained 
10 transgenic embryos with the wild-type transgene (In11-12TBEwt-
lacZ) at E15.5, of which five were -gal+. In these embryos, 
-gal–expressing cells colocalized with anti-Vegfr3 in LECs 
of the mesenteric lymphatic vessels (Fig. 5, D and E) and in 
lymphatic vessels of the skin and heart (not depicted). We also 
Figure 5. Tbx1 regulates VEGFR3 expres-
sion via a conserved TBE in the endogenous 
VEGFR3 gene. (A) Schematic of the In11-12TBE 
luciferase reporter. A mutant version of the re-
porter construct was generated by site-directed 
mutagenesis of the TBE located within the 
putative VEGFR3 enhancer (In11-12TBE). (B) Co-
transfection of JEG3 cells with the luciferase 
reporter and increasing amounts of Tbx1 ex-
pression vector increased activity of the lucifer-
ase reporter containing the wild-type enhancer 
(wt-TBE) but not the mutant enhancer (mut-TBE). 
Control cultures were transfected with empty ex-
pression vector. (C) PCR of chromatin immuno-
precipitated from HUVECs. Antibodies used 
for immunoprecipitation are indicated above 
the panel. A chromatin sample immuno-
precipitated with a nonspecific antibody 
(c-Myc) served as a negative control and the 
input sample as a positive control. Samples 
immunoprecipitated with anti-Tbx1 showed en-
richment of the VEGFR3 enhancer containing 
the conserved TBE. (D–E) Histological sections 
of the mesentery of transgenic embryos car-
rying the wild-type (D and E) or mutant TBE 
(D’ and E’) enhancer construct at E15.5. Colo-
calization of -gal expression and anti-Vegfr3 
immunostaining was seen in mesenteric LECs 
of transgenic embryos carrying the wild-type 
TBE (D and E, arrowheads) but not with 
the mutated TBE (D’ and E’). Arrows indicate 
the mesenteric artery (A). V, mesenteric vein; 
L, lymphatic vessel. Bars, 100 µm.
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being developed as anticancer agents. It would be interesting to 
investigate whether VEGFR3 expression in the vicinity of solid 
tumors is regulated by TBX1.
Materials and methods
Mouse lines
The following mouse lines were used: Tbx1lacz/+ (Lindsay et al., 2001), 
Tbx1flox/+ (Xu et al., 2004), Tie2Cre (Kisanuki et al., 2001), R26R (Soriano, 
1999), TgCAGG-CreERTM (Hayashi and McMahon, 2002), Tbx1E5/+  
(Xu et al., 2004), and Tbx1Cre/+ (Huynh et al., 2007). Genotyping was 
performed according to the aforementioned original reports. Activation of 
CAGG-CreERTM was performed with a single intraperitoneal injection of 
75 mg/kg body weight TM (Xu et al., 2005).
X-gal staining, immunostaining, and immunocytofluorescence
-Gal activity was revealed on 4% PFA-fixed samples by X-gal staining. 
Samples were photographed directly or paraffin embedded and sectioned 
at 10 µm. Immunostaining and immunocytofluorescence were performed 
using the following antibodies: rat anti–Vegfr3 (eBioscience), rat anti–
PECAM-1 (BD), rabbit anti-Lyve1 (Abcam), monoclonal anti-VEGFD (R&D 
Systems), and rabbit anti-IGF1 (Santa Cruz Biotechnology, Inc.). Nonfluo-
rescent antibodies were visualized after mounting slides in Cytoseal 
(Thermo Fisher Scientific). Fluorescent antibodies were visualized using 
imaging medium (Vectashield; Vector Laboratories). Whole-mount speci-
mens were photographed using a dissecting microscope (Stemi 2000; 
Carl Zeiss, Inc.) equipped with a camera (Axiocam; Carl Zeiss, Inc.) and 
the manufacturer’s acquisition software. Images of histological sections 
were acquired using a microscope (Axioskop 40; Carl Zeiss, Inc.) 
equipped with a camera (Axiocam; Carl Zeiss, Inc.) and the manufactur-
er’s acquisition software. Photoshop (Adobe) was used for trimming and 
labeling images.
Cell manipulations
HUVECs (Lonza) were electroporated with increasing amounts of a TBX1 
expression or with empty vector and an EGFP reporter to monitor transfec-
tion. Transfection of a standard amount of DNA in all samples was 
achieved by adjusting the quantity of empty vector in the mix. After 24 h, 
cells were fixed in 4% PFA for immunocytofluorescence or lysed for RNA 
isolation. qRT-PCR was performed using commercial primers (RT2Profiler 
PCR Array; PAHS-024; human angiogenesis; QIAGEN).
RNA interference was performed using commercial siRNA for TBX1 
(ON-TARGETplus SMARTpool; Thermo Fisher Scientific) and a control 
siRNA (Thermo Fisher Scientific). HUVECs or HMLECs were transfected 
with 40 nM siRNA and Lipofectamine 2000 (Invitrogen). TBX1 mRNA was 
evaluated by qRT-PCR, and TBX1 protein was evaluated by Western blot-
ting with anti-Tbx1 (Invitrogen). Protein levels were normalized to anti– 
-actin (Sigma-Aldrich).
Enhancer activity assays
For the luciferase construct, a 1.1-kb of DNA surrounding a conserved TBE 
in the Vegfr3 intron 11-12 was PCR amplified with primers 5-CGAGACT-
GGAAGGAGGTGACC-3 and 5-CACCAGCTTGCTCACCGTC-3. The 
amplicon, named In11-12TBE, was first cloned into a T-vector, pCRII-TOPO 
(Invitrogen), and after KpnI–XhoI digestion, it was subcloned into a pGL3 
luciferase expression vector (Promega). Subsequently, the enhancer frag-
ment was subjected to site-directed mutagenesis of the TBE. The native se-
quence 5-TACACACCTCCA-3 was mutated to 5-TACGGGCCTCCA-3 
using a site-directed mutagenesis kit (QuikChange XL; Agilent Technolo-
gies). A Tbx1 expression vector was cotransfected with the enhancer 
reporter (wild type or mutated) into JEG3 cells, which were harvested 
48 h later. JEG3 cells transfected with empty expression vector, and with-
out the enhancer reporter, constituted the control sample. Experiments were 
performed in triplicate and repeated twice.
In11-12TBEwt-HSPlacZ and In11-12TBEmut-HSPlacZ transgenes were 
injected into FVB/NCr pronuclei. Embryos were harvested at E15.5, 
stained with X-gal, and genotyped by PCR with the following primers: 
TT_LaczF, 5-CTGGAATTCCGCCGATACT-3; TT_LaczR, 5-CCGGATTGAT-
GGTAGTGGTC-3; TT_VR3F, 5-GCCTCTGTTCTGGGTAGACG-3; and 
TT_VR3R, 5-AGTGCTGCCTCTGACCTCAT-3.
ChIP
ChIP experiments were performed as described previously (Breiling et al., 
2004). Chromatin from cross-linked HUVECs cells was immunoprecipitated 
Thus, Tbx1 is not essential for lymphangiogenesis per se; rather, 
it is required for the development of the lymphatic network. We 
have gained insights into when and how Tbx1 functions in mes-
enteric lymphatic development. On a Tbx1-null background, lym-
phatic vessels form at the appropriate time, but they are highly 
disorganized and fail to extend distally. Between E15.5 and 
E16.5, these abnormal lymphatic vessels are lost, most likely as 
a result of cell death. This suggests that Tbx1 has at least two 
roles in the mesentery. First, it is required for growth and expan-
sion of the lymphatic network. This is consistent with our data 
from cultured LECs that show increased cell proliferation in re-
sponse to Tbx1 transfection. Second, it is required to maintain 
mesenteric lymphatic vessels.
In a search for potential effectors of these functions, we 
found that the expression of Vegfr3 is not maintained in Tbx1lacz/lacz 
mutants or in Tie2-Cre; Tbx1flox/lacz mutants. Through tissue cul-
ture and in vivo genetic experiments, we have demonstrated that 
Vegfr3 is a direct transcriptional target of Tbx1 and identified a 
Tbx1-responsive element in the Vegfr3 gene. Thus, we have 
directly linked Tbx1 to an essential lymphangiogenesis sig-
naling pathway.
Our data support the hypothesis that, in the absence of 
Tbx1, lymphatic vessels are not maintained, secondary to a 
failure to maintain Vegfr3 expression LECs. This hypothesis is 
consistent with in vitro and in vivo studies that have shown a 
critical role for VEGF-C/Vegfr3 signaling in the growth, 
migration, and survival of LECs (Mäkinen et al., 2001a,b; 
Veikkola et al., 2001).
Could loss of Vegfr3 in Tbx1-null ECs account for the 
entire lymphatic phenotype of Tbx1-null mutants? In the future, 
it will be interesting to see whether forced expression of Vegfr3 
in ECs rescues lymphatic defects in Tbx1 mutants.
How is Tbx1 regulated? There is very little information to 
date. A Forkhead (Fox) transcription factor–responsive element 
has been identified upstream of the Tbx1 gene (Yamagishi et al., 
2003). The enhancer responds in tissue culture to Foxc2, which 
has also been involved in lymphatic development (for review 
see Tammela et al., 2005). However, it is unknown whether 
Foxc2 is required for Tbx1 expression in endothelium, and, 
in any case, the phenotypes resulting from Tbx1 and Foxc1 or 
Foxc2 loss of function are different. In particular, Foxc1/2 has a 
later role in lymphangiogenesis compared with Tbx1 (Norrmén 
et al., 2009).
TBX1 mutations can cause DiGeorge syndrome, but lym-
phatic defects have not been reported as part of the clinical 
spectrum associated with this disease. As the human disease is 
caused by heterozygous mutations, it is possible that a single 
copy of TBX1 is sufficient to support normal lymphatic vessels. 
Alternatively, the defects may be subclinical. Our findings 
should stimulate the search for subtle defects in patients. Pos-
sible consequences of mild lymphatic abnormalities in the GI 
tract may be reduced absorption of lipids and resulting growth 
delay, a common finding in affected infants (Ryan et al., 1997; 
Scambler, 2000; Emanuel et al., 2001). Another question raised 
by this study is whether TBX1 plays a role in cancer. Many studies 
have linked tumor lymphangiogenesis to the development of 
lymph node metastases, and VEGFR3 inhibitors are currently 
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